Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.
Medincell (OTCPK:MDCLF) Tangible Book per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Medincell Tangible Book per Share Related Terms
Medincell Tangible Book per Share Historical Data
* Premium members only.
The historical data trend for Medincell's Tangible Book per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDCLF vs VRTX, REGN, ALNY: Tangible Book per Share Comparison
For the Biotechnology subindustry, Medincell's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medincell Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medincell's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Medincell's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.
What does a Tangible Book per Share of $0.10 mean?
Medincell (MDCLF) has a Tangible Book per Share of $0.10 as of Mar. 2026. Tangible book per share equals the per-share value of a company's tangible equity. View historical data on Medincell and its competitors.
Is Medincell's Tangible Book per Share too high?
Medincell's current Tangible Book per Share is $0.10. Overall, Medincell has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's Tangible Book per Share compare to VRTX and REGN?
Medincell's Tangible Book per Share of $0.10 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tangible Book per Share for a Biotechnology company?
A good Tangible Book per Share depends on the Biotechnology industry context. However, Tangible Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tangible Book per Share mean?
A high Tangible Book per Share can signal that a stock is expensive relative to its fundamentals. Tangible book per share equals the per-share value of a company's tangible equity. View historical data on Medincell and its competitors. Medincell's current Tangible Book per Share is $0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current Tangible Book per Share of $0.10. The stock's GF Value™ is $27.51, compared to a current price of $34.39 — trading 25% above its estimated fair value. The current Tangible Book per Share is $0.10. Medincell's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tangible Book per Share calculated?
Tangible Book per Share is calculated from a company's financial statements. For Medincell (MDCLF), the current Tangible Book per Share is $0.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medincell (MDCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Medincell stock appears to be overvalued.
The current stock price of $34.39 is trading 25% above its estimated GF Value™ of $27.51.
Key valuation signals for MDCLF:
Tangible Book per Share: $0.10
GF Value™: $27.51 vs. price of $34.39 (25% above fair value)
No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score
Get the complete analysis for MDCLF
Tangible Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDCLF has been successfully added to your 
